The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches

The beginning of the end for conventional RECIST — novel therapies require novel imaging approachesThe beginning of the end for conventional RECIST — novel therapies require novel imaging approaches, Published online: 04 February 2019; doi:10.1038/s41571-019-0169-5The development of more-targeted cancer therapies has not been matched by more-targeted imaging methods. This discrepancy has, in some scenarios, resulted in inaccurate assessments of the effects of novel therapies. In this Review, the authors describe potential novel imaging approaches that could be adopted to enable improvements in imaging-based monitoring of treatment responses and resistance.

Source: Nature Clinical Practice Oncology - February 4, 2019 Category: Cancer & Oncology Authors: Mirjam Gerwing Ken Herrmann Anne Helfen Christoph Schliemann Wolfgang E. Berdel Michel Eisenbl ätter Moritz Wildgruber Source Type: research